Experts Warn of Risks in Mainstream Peptide Trend
While peptides are a dominant wellness trend, experts are warning of potential health risks associated with compounds like BPC-157 that are not FDA-approved and often sourced from gray markets. The trend is fueled by the widespread adoption of GLP-1 drugs, with an estimated 12% of Americans having used them.
- The global peptide therapeutics market was valued at approximately $117.26 billion in 2024 and is projected to grow to over $260 billion by 2030. North America currently accounts for the largest market share. - The U.S. Food and Drug Administration (FDA) has not approved BPC-157 for human use; it is classified as an unapproved drug. The FDA has placed it in "Category 2" on its bulk drug substances list, meaning compounding pharmacies are prohibited from using it in medications for humans due to safety concerns. - Unregulated "research-only" peptides sourced from the gray market carry significant contamination risks, including bacterial byproducts (endotoxins), heavy metals, residual solvents from synthesis, and incorrect or incomplete peptide chains. - In late 2023, the FDA cracked down on 17 popular peptides, including CJC-1295 and Ipamorelin, by categorizing them as substances that pose safety concerns, effectively telling traditional compounding pharmacies not to compound them. - BPC-157 has been banned by the World Anti-Doping Agency (WADA) since 2022, where it is classified under the S0 category of "Non-Approved Substances." This makes its presence in any wellness or sports nutrition product a significant compliance risk for athletes. - The rise in peptide interest aligns with a broader consumer trend shifting away from "clean" or "natural" ingredients towards products promising "clinical effectiveness." On The Vitamin Shoppe's website alone, searches for peptides surged by 550%. - While personal possession of unapproved peptides like BPC-157 exists in a legal gray area, it is illegal to market and sell them for human consumption. Some states, like New York, have begun passing laws that ban the sale of muscle-building and weight-loss supplements to minors, which could impact how peptides are marketed and sold. - Despite preclinical animal studies suggesting benefits for tissue healing, there is a significant lack of published human clinical trial data for BPC-157 to establish its safety and effectiveness. Potential side effects discussed based on its mechanisms include unwanted blood vessel formation (angiogenesis), which could accelerate undetected cancer growth.
